

Medical Coverage Policy | Progenitor Cell Therapy for the Treatment of Damaged Myocardium due to Ischemia



EFFECTIVE DATE: 02|01|2017

POLICY LAST UPDATED: 06|07|2023

OVERVIEW

Progenitor cell therapy describes the use of multipotent cells of various cell lineages (autologous or allogeneic) for tissue repair and/or regeneration. Progenitor cell therapy is being investigated for the treatment of damaged myocardium resulting from acute or chronic cardiac ischemia and for refractory angina.

MEDICAL CRITERIA

Not applicable

PRIOR AUTHORIZATION

Not applicable

POLICY STATEMENT

Medicare Advantage Plans

Progenitor cell therapy, including but not limited to skeletal myoblasts or hematopoietic cells, is considered not covered as a treatment of damaged myocardium as the evidence is insufficient to determine the effects of the technology on health outcomes.

Infusion of growth factors (ie, granulocyte colony stimulating factor) is considered not covered as a technique to increase the numbers of circulating hematopoietic cells as treatment of damaged myocardium as the evidence is insufficient to determine the effects of the technology on health outcomes.

Commercial Products

Progenitor cell therapy, including but not limited to skeletal myoblasts or hematopoietic cells, is considered not medically necessary as a treatment of damaged myocardium as the evidence is insufficient to determine the effects of the technology on health outcomes.

Infusion of growth factors (ie, granulocyte colony stimulating factor) is considered not medically necessary as a technique to increase the numbers of circulating hematopoietic cells as treatment of damaged myocardium as the evidence is insufficient to determine the effects of the technology on health outcomes.

COVERAGE

Benefits may vary between groups and contracts. Please refer to the appropriate Benefit Booklet, Evidence of Coverage or Subscriber Agreement for applicable not medically necessity/not covered benefits/coverage.

BACKGROUND

Ischemia is the most common cause of cardiovascular disease and myocardial damage in the developed world. Despite impressive advances in treatment, ischemic heart disease is still associated with high morbidity and mortality. According to the American Heart Association, coronary heart disease has a prevalence of 5.7% among White people, 5.4% among Black people, 8.6% among American Indian/Alaska Native people, and 4.4% among Asian people. For all age strata, the incidence of myocardial infarction is higher in Black males than in Black females, White males, and White females. Heart failure has the highest prevalence among Black males (3.8%) followed by Black females (3.3%), White males (2.9%), Hispanic males (1.8%), Hispanic and White females (both 1.6%), Asian males (1.4%), and Asian females (0.5%). Age-adjusted death rates per 100,000

individuals with coronary heart disease and heart failure are higher for Black males and females than their counterparts of other races.

Current treatments for ischemic heart disease seek to revascularize occluded arteries, optimize pump function, and prevent future myocardial damage. However, current treatments do not reverse existing heart muscle damage. Treatment with progenitor cells (ie, stem cells) offers potential benefits beyond those of standard medical care, including the potential for repair and/or regeneration of damaged myocardium. Potential sources of embryonic and adult donor cells include skeletal myoblasts, bone marrow cells, circulating blood-derived progenitor cells, endometrial mesenchymal stem cells, adult testis pluripotent stem cells, mesothelial cells, adipose-derived stromal cells, embryonic cells, induced pluripotent stem cells, and bone marrow mesenchymal stem cells, all of which can differentiate into cardiomyocytes and vascular endothelial cells for regenerative medicine advanced therapy (RMAT). The RMAT designation may be given if: (1) the drug is a regenerative medicine therapy (ie, a cell therapy), therapeutic tissue engineering product, human cell and tissue product, or any combination product; (2) the drug is intended to treat, modify, reverse, or cure a serious or life-threatening disease or condition; and (3) preliminary clinical evidence indicates that the drug has the potential to address unmet medical needs.

For individuals who have acute cardiac ischemia who receive progenitor cell therapy, the evidence includes 2 phase 3 RCTs, numerous small, early-phase RCTs, and meta-analyses of these RCTs. Relevant outcomes are disease-specific survival, morbid events, functional outcomes, quality of life, and hospitalizations. Limited evidence on clinical outcomes has suggested there maybe benefits from improving LVEF, reducing recurrent MI, decreasing the need for further revascularization, and perhaps decreasing mortality, although, a recent, large, individual patient data meta-analysis reported no improvement in these outcomes. No adequately powered trial has reported benefits in clinical outcomes (eg, mortality, adverse cardiac outcomes, exercisecapacity, quality of life). Overall, this evidence has suggested that progenitor cell treatment may be a promising intervention, but robust data on clinical outcomes are lacking. High-quality RCTs, powered to detect differences in clinical outcomes, are needed to answer this question. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

For individuals who have chronic cardiac ischemia who receive progenitor cell therapy, the evidence includes 1 phase 3 RCT with more than 100 participants, 2 phase 2 RCTs with more than 100 participants, systematic reviews of smaller, early-phase RCTs, and a nonrandomized comparative trial. Relevant outcomes are disease-specific survival, morbid events, functional outcomes, quality of life, and hospitalizations. The studies included in the meta-analyses have reported only on a small number of clinical outcome events. Two phase 2 RCTs (CONCERT-HF and ixCELL-DCM) found significant benefit on heart failure-related death and other cardiac events with cell therapy compared to placebo. A well-conducted phase 3 trial failed to demonstrate superiority of cell therapy for its primary composite outcome that included death, worsening heart failure events, and other multiple events. The nonrandomized STAR-Heart trial showed a mortality benefit as well as favorable hemodynamic effect, but a lack of randomization limits interpretation due to the concern about selection bias and differences in known and unknown prognostic variables at baseline between both arms. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

For individuals who have refractory angina who receive progenitor cell therapy, the evidence includes a systematic review of RCTs, phase 2 trials, and a phase 3 pivotal trial. Relevant outcomes are disease-specific survival, morbid events, functional outcomes, quality of life, and hospitalizations. The only phase 3 trial identified was terminated early and insufficiently powered to evaluate clinical outcomes. Additional larger trials are needed to determine whether progenitor cell therapy improves health outcomes in patients with refractory angina. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

Regulatory Status

Multiple progenitor cell therapies such as MyoCell® (U.S. Stem Cell, formerly Bioheart), Ixmyelocel-T (Vericel, formerly Aastrom Biosciences), MultiStem® (Athersys), and CardiAMP™ (BioCardia) are being commercially developed, but none has been approved by the U.S. Food and Drug Administration (FDA) so far.

MyoCell comprises patient autologous skeletal myoblasts that are expanded ex vivo and supplied as a cell suspension in a buffered salt solution for injection into the area of damaged myocardium. In 2017, U.S. Stem Cell reprioritized its efforts away from seeking RMAT designation for MyoCell. The expanded cell product enriched for mesenchymal and macrophage lineages might enhance potency. Vericel has received RMAT designation for Ixmyelocel-T.

MultiStem is an allogeneic bone marrow-derived adherent adult stem cell product that has received RMAT designation.

The CardiAMP Cell Therapy system consists of a proprietary assay to identify patients with a high probability to respond to autologous cell therapy, a proprietary cell processing system to isolate process and concentrate the stem cells from a bone marrow harvest at the point of care, and a proprietary delivery system to percutaneously inject the autologous cells into the myocardium. BioCardia has received an investigational device exemption from the FDA to perform a trial of CardiAMP and is designated as an FDA Breakthrough Device.

CODING

Medicare Advantage Plans and Commercial Products

There are no specific code(s) for this procedure, either describing the laboratory component of processing the harvested autologous cells or for the implantation procedure. Claims should be filed with an unlisted CPT code(s).

RELATED POLICIES

Unlisted Procedures

PUBLISHED

Provider Update, August 2023

Provider Update, September 2022

Provider Update, July 2021

Provider Update, January/August 2020

REFERENCES:

1. Tsao CW, Aday AW, Almarzooq ZI, et al. Heart Disease and Stroke Statistics-2023 Update: A Report From the American Heart Association. *Circulation*. Feb 21 2023; 147(8): e93-e621. PMID 36695182
2. Lee MS, Makkar RR. Stem-cell transplantation in myocardial infarction: a status report. *Ann Intern Med*. May 04 2004;140(9): 729-37. PMID 15126257
3. U.S. Food and Drug Administration. Regenerative Medicine Advanced Therapy Designation. 2023; <https://www.fda.gov/BiologicsBloodVaccines/CellularGeneTherapyProducts/ucm537670.htm>. Accessed March 13, 2023.
4. Delewi R, Hirsch A, Tijssen JG, et al. Impact of intracoronary bone marrow cell therapy on left ventricular function in the setting of ST-segment elevation myocardial infarction: a collaborative meta-analysis. *Eur Heart J*. Apr 2014; 35(15): 989-98. PMID 24026778
5. de Jong R, Houtgraaf JH, Samiei S, et al. Intracoronary stem cell infusion after acute myocardial infarction: a meta-analysis and update on clinical trials. *Circ Cardiovasc Interv*. Apr 2014; 7(2): 156-67. PMID 24668227
6. Fisher SA, Zhang H, Doree C, et al. Stem cell treatment for acute myocardial infarction. *Cochrane Database Syst Rev*. Sep 30 2015; 2015(9): CD006536. PMID 264199137.
7. Gyöngyösi M, Wojakowski W, Lemarchand P, et al. Meta-Analysis of Cell-based CaRdiac stUdiEs (ACCRUE) in patients with acute myocardial infarction based on individual patient data. *Circ Res*. Apr 10 2015; 116(8): 1346-60. PMID 25700037

8. Fisher SA, Doree C, Taggart DP, et al. Cell therapy for heart disease: Trial sequential analyses of two Cochrane reviews. *Clin Pharmacol Ther.* Jul 2016; 100(1): 88-101. PMID 26818743
9. Lalu MM, Mazzarello S, Zlepnig J, et al. Safety and Efficacy of Adult Stem Cell Therapy for Acute Myocardial Infarction and Ischemic Heart Failure (SafeCell Heart): A Systematic Review and Meta-Analysis. *Stem Cells Transl Med.* Dec 2018;7(12): 857-866. PMID 30255989
10. Moazzami K, Roohi A, Moazzami B. Granulocyte colony stimulating factor therapy for acute myocardial infarction. *Cochrane Database Syst Rev.* May 31 2013; 2013(5): CD008844. PMID 23728682
11. Schächinger V, Erbs S, Elsässer A, et al. Improved clinical outcome after intracoronary administration of bone-marrow-derived progenitor cells in acute myocardial infarction: final 1-year results of the REPAIR-AMI trial. *Eur Heart J.* Dec 2006;27(23): 2775-83. PMID 17098754
12. Schächinger V, Erbs S, Elsässer A, et al. Intracoronary bone marrow-derived progenitor cells in acute myocardial infarction. *N Engl J Med.* Sep 21 2006; 355(12): 1210-21. PMID 16990384
13. Assmus B, Rolf A, Erbs S, et al. Clinical outcome 2 years after intracoronary administration of bone marrow-derived progenitor cells in acute myocardial infarction. *Circ Heart Fail.* Jan 2010; 3(1): 89-96. PMID 19996415
14. Hirsch A, Nijveldt R, van der Vleuten PA, et al. Intracoronary infusion of mononuclear cells from bone marrow or peripheral blood compared with standard therapy in patients after acute myocardial infarction treated by primary percutaneous coronary intervention: results of the randomized controlled HEBE trial. *Eur Heart J.* Jul 2011; 32(14): 1736-47. PMID 21148540
15. Fisher SA, Doree C, Mathur A, et al. Stem cell therapy for chronic ischaemic heart disease and congestive heart failure. *Cochrane Database Syst Rev.* Dec 24 2016; 12(12): CD007888. PMID 28012165
16. Fisher SA, Brunskill SJ, Doree C, et al. Stem cell therapy for chronic ischaemic heart disease and congestive heart failure. *Cochrane Database Syst Rev.* Apr 29 2014; (4): CD007888. PMID 24777540
17. Xu R, Ding S, Zhao Y, et al. Autologous transplantation of bone marrow/blood-derived cells for chronic ischemic heart disease: a systematic review and meta-analysis. *Can J Cardiol.* Nov 2014; 30(11): 1370-7. PMID 24726092
18. Xiao C, Zhou S, Liu Y, et al. Efficacy and safety of bone marrow cell transplantation for chronic ischemic heart disease: a meta-analysis. *Med Sci Monit.* Oct 01 2014; 20: 1768-77. PMID 25270584
19. Bolli R, Mitrani RD, Hare JM, et al. A Phase II study of autologous mesenchymal stromal cells and c-kit positive cardiac cells, alone or in combination, in patients with ischaemic heart failure: the CCTRN CONCERT-HF trial. *Eur J Heart Fail.* Apr 2021; 23(4): 661-674. PMID 33811444
20. Bartunek J, Terzic A, Davison BA, et al. Cardiopoietic cell therapy for advanced ischaemic heart failure: results at 39 weeks of the prospective, randomized, double blind, sham-controlled CHART-1 clinical trial. *Eur Heart J.* Mar 01 2017;38(9): 648-660. PMID 28025189
21. Bartunek J, Terzic A, Davison BA, et al. Cardiopoietic stem cell therapy in ischaemic heart failure: long-term clinical outcomes. *ESC Heart Fail.* Dec 2020; 7(6): 3345-3354. PMID 33094909
22. Patel AN, Henry TD, Quyyumi AA, et al. Ixmyelocel-T for patients with ischaemic heart failure: a prospective randomised double-blind trial. *Lancet.* Jun 11 2016; 387(10036): 2412-21. PMID 27059887
23. Pokushalov E, Romanov A, Chernyavsky A, et al. Efficiency of intramyocardial injections of autologous bone marrow mononuclear cells in patients with ischemic heart failure: a randomized study. *J Cardiovasc Transl Res.* Apr 2010; 3(2):160-8. PMID 20560030

11

[CLICK THE ENVELOPE ICON BELOW TO SUBMIT COMMENTS](#)

This medical policy is made available to you for informational purposes only. It is not a guarantee of payment or a substitute for your medical judgment in the treatment of your patients. Benefits and eligibility are determined by the member's subscriber agreement or member certificate and/or the employer agreement, and those documents will supersede the provisions of this medical policy. For information on member-specific benefits, call the provider call center. If you provide services to a member which are determined to not be medically necessary (or in some cases medically necessary services which are non-covered benefits), you may not charge the member for the services unless you have informed the member and they have agreed in writing in advance to continue with the treatment at their own expense. Please refer to your participation agreement(s) for the applicable provisions. This policy is current at the time of publication; however, medical practices, technology, and knowledge are constantly changing. BCBSRI reserves the right to review and revise this policy for any reason and at any time, with or without notice. Blue Cross & Blue Shield of Rhode Island is an independent licensee of the Blue Cross and Blue Shield Association.

